Benchmark analyst Bruce Jackson raised the firm’s price target on Belite Bio (BLTE) to $132 from $80 and keeps a Buy rating on the shares. Belite is “approaching a series of major catalysts,” beginning with the release of topline results during Q4 from the Phase 3 DRAGON study of Tinlarebant in Stargardts Disease, the analyst tells investors. The results, which are likely to be positive in the firm’s view, combined with orphan drug designation, could result in attractive pricing, leading the firm to increase its pricing assumptions for the drug.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio management to meet virtually with Cantor
- Belite Bio files to sell 1.95M American Depositary Shares for holders
- Leerink bullish on Belite Bio, says tinlarebant news another positive data point
- Belite Bio announces China’s NMPA agreed to accept NDA for Tinlarebant
- Belite Bio price target lowered to $98 from $100 at H.C. Wainwright